herbert hoover

Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up

There seem to be a few biotechs that generate tons of shorting by a certain Big Player - look what was done to DNDN. Unfortunately there seems to be a concerted effort to actively short SPPI in the same manner. Basically the same players, using the same methods, in a very methodical manner.

I dumped my shares because of this.

Study Says Price Controls Bad for Drug Firms and Consumers

Pharma profits will also sink once Obama abandons the Bush policies that prohibited drug pricing negotiations. Their future earnings are going to plummet